Small Molecule Drugs

Small Molecule Drugs includes companies developing orally available or otherwise chemically synthesized medicines built from relatively low-molecular-weight compounds. This remains one of the broadest and most commercially important categories in biotech and pharma.

Why watch Small Molecule Drugs

This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.

Latest Small Molecule Drugs news

The latest feed items from companies currently grouped under Small Molecule Drugs.

1. 01
   2026-11-05 21:38 EST

   CRISCuris to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026

   Source: Curis Inc

2. 02
   2026-11-05 15:08 EST

   GSKGSK showcases progress in liver portfolio at AASLD 2026

   Source: GSK plc

3. 03
   2026-11-04 21:05 EST

   INVAInnoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress

   Source: Innoviva

4. 04
   2026-11-04 21:01 EST

   BCRXBioCryst to Present at Upcoming Investor Conferences

   Source: BioCryst Pharmaceuticals

5. 05
   2026-11-04 13:00 EST

   PMVPPivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026

   Source: PMV Pharmaceuticals

6. 06
   2026-11-04 12:00 EST

   BCRXBioCryst Reports Third Quarter 2026 Financial Results

   Source: BioCryst Pharmaceuticals

7. 07
   2026-11-04 12:00 EST

   ENTAEnanta Pharmaceuticals to Participate in Upcoming Investor Conferences

   Source: Enanta Pharmaceuticals

8. 08
   2026-11-03 21:05 EST

   EXELExelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

   Source: Exelixis

9. 09
   2026-11-02 22:00 EST

   ZNTLZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   Source: Zentalis

10. 10
    2026-10-29 20:05 EST

    EXELExelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

    Source: Exelixis

11. 11
    2026-10-29 11:00 EST

    BCRXBioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting

    Source: BioCryst Pharmaceuticals

12. 12
    2026-10-28 16:50 EST

    JNJRYBREVANT®▼ (amivantamab) sous-cutané affiche un taux de réponse objective de 77 pour cent en traitement de première ligne chez des patients atteints de certaines formes avancées de cancer de la tête et du cou

    Source: Johnson & Johnson

13. 13
    2026-10-28 11:00 EST

    ENTAEnanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership

    Source: Enanta Pharmaceuticals

14. 14
    2026-10-28 07:00 EST

    GSKGSK delivers strong Q3 performance and continued momentum

    Source: GSK plc

15. 15
    2026-10-28 06:00 EST

    RHHBYRoche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma

    Source: Roche Holdings AG

16. 16
    2026-10-27 06:00 EST

    RHHBYRoche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories

    Source: Roche Holdings AG

17. 17
    2026-10-26 15:30 EST

    GSKRis-Rez reduced risk of disease progression or death by 67% versus chemotherapy in patients with relapsed osteosarcoma in China

    Source: GSK plc

18. 18
    2026-10-26 11:00 EST

    ENTAEnanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)

    Source: Enanta Pharmaceuticals

19. 19
    2026-10-25 15:30 EST

    RHHBYRoche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer

    Source: Roche Holdings AG

20. 20
    2026-10-25 14:24 EST

    JNJSubcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer

    Source: Johnson & Johnson

Companies in Small Molecule Drugs

21 companies tagged with Small Molecule Drugs.

Frequently Asked Questions